Disease Markers / 2015 / Article / Tab 1

Research Article

The Prognostic Value of Intermedin in Patients with Breast Cancer

Table 1

The factors associated with mortality and adverse events during 5-year follow-up.

CharacteristicsMortalityAdverse event
YesNo valueYesNo value

Number6019288164
Age0.1700.352
 ≤44 y23 (38.3%)93 (48.4%)37 (42.0%)79 (48.2%)
 ≥45 y37 (61.7%)99 (51.6%)51 (58.0%)85 (51.8%)
Menopausal status0.0300.010
 Premenopausal30 (50.0%)126 (65.6%)45 (51.1%)111 (67.7%)
 Postmenopausal30 (50.0%)66 (34.4%)43 (48.9%)53 (32.3%)
Tumor size0.0010.005
 <2 cm22 (36.7%)117 (60.9%)38 (43.2%)101 (61.6%)
 ≥2 cm38 (63.3%)75 (39.1%)50 (56.8%)63 (38.4%)
Tumor-mode-metastasis stage0.0030.011
 I, II33 (55.0%)144 (75.0%)53 (60.2%)124 (75.6%)
 III27 (45.0%)48 (25.0%)35 (39.8%)40 (24.4%)
Lymph node status<0.001<0.001
 Negative21 (35.0%)124 (64.6%)36 (40.9%)109 (66.5%)
 Positive39 (65.0%)68 (35.4%)52 (59.1%)55 (33.5%)
Histologic grade<0.0010.002
 I, II22 (36.7%)120 (62.5%)38 (43.2%)104 (63.4%)
 III38 (63.3%)72 (37.5%)50 (56.8%)60 (36.6%)
Nuclear grade0.0010.007
 I, II22 (36.7%)116 (60.4%)38 (43.2%)100 (61.0%)
 III38 (63.3%)76 (39.6%)50 (56.8%)64 (39.0%)
Estrogen receptor status<0.0010.001
 Positive21 (35.0%)122 (63.5%)37 (42.1%)106 (64.6%)
 Negative39 (65.0%)70 (36.5%)51 (57.9%)58 (35.4%)
Progesterone receptor status0.0030.015
 Positive23 (38.3%)115 (60.0%)39 (44.3%)99 (60.4%)
 Negative37 (61.7%)77 (40.0%)49 (55.7%)65 (39.6%)
Intermedin<0.001<0.001
 Low intermedin level15 (25.0%)135 (70.3%)26 (29.6%)124 (75.6%)
 High intermedin level45 (75.0%)57 (29.7%)62 (70.4%)40 (24.4%)

Variables were presented as counts (percentage). Intergroup comparisons were completed by Chi-square test or Fisher exact test.